BioCorRx Inc. (OTCQB: BICX) announced that Louis Lucido has been appointed Chair of the Company's Board of Directors, effective January 1, 2026, in a planned leadership transition within the existing Board. Mr. Lucido succeeded Kent Emry, who has served on BioCorRx's Board of Directors since 2013 and will continue to serve as an independent director, ensuring continuity of leadership and governance. This transition matters because stable governance is critical for companies developing treatments for substance use disorders, which affect millions globally, including the more than 16.6 million people who have used methamphetamine according to the National Survey on Drug Use and Health.
Mr. Lucido has been a member of the BioCorRx Board of Directors since 2019 and has played an instrumental role in the Company's development and supporting operational leadership during a pivotal period for the Company as President since 2024. His extensive board leadership experience, including service as Chair of the Board for other organizations, positions him well to lead BioCorRx as it advances its strategic objectives. The company's focus includes addressing opioid use disorder (OUD), a chronic disorder with serious potential consequences including disability, relapses, and death, through treatments like LUCEMYRA® (lofexidine), an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults.
Lourdes Felix, Chief Executive Officer of BioCorRx, stated, "We thank Kent for his dedicated service and leadership since 2013. His guidance has been instrumental during key periods for the Company. We are pleased to appoint Louis as Board Chair, reflecting his deep understanding of BioCorRx, his leadership as President, and his extensive experience serving as Board Chair with other organizations." Mr. Lucido added, "I am honored to step into the role of Board Chair. With a deep understanding of the Company developed through years of Board service, I look forward to working with the Board and management to support disciplined execution and long-term growth."
The leadership continuity is significant as BioCorRx advances multiple treatment programs. The company's Beat Addiction Recovery program includes proprietary Cognitive Behavioral Therapy modules along with peer support via mobile app and medication prescribed by an independent treating physician. Additionally, BioCorRx operates through its subsidiary, BioCorRx Pharmaceuticals Inc., which focuses on pharmaceutical commercialization and development, including LUCEMYRA® and the development of BICX104, an investigational implantable naltrexone pellet program. Research for BICX104 was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994.
Beyond substance abuse treatment, BioCorRx addresses obesity through the UnCraveRx® Weight Loss Program, a medication-assisted program that includes access to concierge on-demand wellness specialists. This is important given global health concerns, as the World Health Organization reported in 2024 that one in eight people live with obesity, with estimates suggesting the global obesity crisis could affect over 4 billion people by 2035. The company's diversified approach to addiction and related disorders underscores the importance of experienced leadership to navigate complex healthcare landscapes while maintaining focus on patient outcomes and strategic growth initiatives.
